-
Review
-
Korean J Med. 2006;71(1):180-180.
- Could mobilized endothelial and their progenitor cell counts be used as biomarker for treatment efficacy and outcome in gastric cancer patients?
-
Sang Joon Shin, Joong Bae Ahn, Hye Jin Choi, Byoung Chul Cho, Jong Keun Lim, Sung Ha Cheon, Hyun Chang, Jong Yul Jung, Hei-Cheul Jeung, Sun Young Rha, Jae Kyung Roh, Hyun Cheol Chung
-
.
- Could mobilized endothelial and their progenitor cell counts be used as biomarker for treatment efficacy and outcome in gastric cancer patients?
-
, , , , , , , , , , ,
-
Laboratory of Endocrine Cell Biology, Department of Internal Medicine, School of Medicine, Chungnam National University, 640 Daesadong Chungku Daejeon 301-721 Korea. Division of Endocrinology1, Department of Internal Medicine, Eulji University Hospital,1
-
- Abstract
- Objective : We wanted to investigate whether the level of circulating endothelial progenitor cells (CEPCs) and endothelial cells
(CECs) could be used as a surrogate predictor of outcome in patients receiving chemotherapy for gastric cancer. Patients and
Methods
: Circulating progenitor and endothelial cells were enumerated in 49 gastric cancer patients by means of flow
cytometry at the time of baseline, after the first, second cycle treatment of 5-FU, leucovorin and taxotere (FLT). To confirm
the endothelial phenotype, positive staining for specific endothelial cell marker [i.e. CD34, von Willebrand factor, P1H12, CD31]
was used. The changes of CEPCs and CECs and prognostic effect of them during treatment on progression and survival were
investigated. Results : The number of CD34+vWF+ and CD34+ cells were significantly higher in responder than non-responder
to chemotherapy (p=0.012 and p=0.008, respectively). In addition, the level of CD31+ cells determined after the second cycle
chemotherapy significantly decreased compared with the first cycle in the patients who showed response (p=0.026). In
non-responder, however, the level of CD34+ cells significantly increased before the second cycle chemotherapy (p=0.034). In
univariate analysis, the level of CD34+ cells significantly related to the median time to progression (TTP) (6.1 and 4 months in
CD34low and CD34high, respectively, p=0.046) but none of the covariates related to the median overall survival (OS). By
multivariate analysis using a Cox proportional-hazard model, however, the level of markers was not a significant independent
prognostic factor for TTP and OS. Conclusion : Serial monitoring of CEPCs and CECs in blood may serve as an early surrogate
marker of predicting tumor response to chemotherapy and outcome of patients receiving chemotherapy for gastric cancer.
Keywords :
